Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Inhalation Sciences receives service orders from recurring global pharma customers

ISABPress release19.11.2026 klo 09.30

Inhalation Sciences Sweden AB (ISAB) has received service orders totaling EUR 45,000 (approximately SEK 500,000) from two long-standing pharmaceutical customers - a global pharmaceutical company and a leading global generics manufacturer.

The orders relate to service of existing PreciseInhale® instruments and reflect the continued use of ISAB's technology by established customers.

Both customers have worked with ISAB for many years, demonstrating the long-term customer relationships and recurring service opportunities associated with the company's installed instrument base.

Pontus Nobréus, CEO of Inhalation Sciences, comments:

"It's a strong signal of trust when established global customers keep coming back to us for their inhalation research needs. These orders reflect the reliability and scientific rigor of our technology, and we are committed to continuing to deliver the quality our customers depend on."  

For more information, please contact:

Pontus Nobréus, CEO
Email: Pontus.Nobreus@inhalation.se
Phone: +46 72-224 20 07

  

About Inhalation Sciences Sweden AB (publ)
Inhalation Sciences Sweden AB (publ.) is a Swedish contract research organization (CRO) specializing in preclinical research and development within inhaled drugs. With our patented technology platform, PreciseInhale®, we deliver unique, high-resolution and predictive data early in the development process. This enables our clients to optimize decision-making, reduce risk, and accelerate their development projects.